N. Azli
Impact in
- Otorhinolaryngology top 0.5%
- Head and Neck Cancer Studies
- Oncology top 2%
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Neutropenia and Cancer Infections
Papers in
- Oncology 28
- Cancer Treatment and Pharmacology 18
- Viral-associated cancers and disorders 6
- Neutropenia and Cancer Infections 6
- HER2/EGFR in Cancer Research 5
-
- Head and Neck Cancer Studies 11
- Co-authors
- Esteban Cvitkovic (17 shared papers)A. Riva (10 shared papers)Véronique Dièras (7 shared papers)M. Bachouchi (11 shared papers)P. Fumoleau (10 shared papers)P. Wibault (6 shared papers)Jean‐Pierre Armand (7 shared papers)P Pouillart (5 shared papers)
In The Last Decade
N. Azli
35 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 81
- Otorhinolaryngology 465
- Oncology 1.4k
- Dermatology 323
- Cancer Research 494
- Pulmonary and Respiratory Medicine 275
Countries citing papers authored by N. Azli
This map shows the geographic impact of N. Azli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Azli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Azli more than expected).
Fields of papers citing papers by N. Azli
This network shows the impact of papers produced by N. Azli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Azli. The network helps show where N. Azli may publish in the future.
Co-authors
The 25 scholars most cited alongside N. Azli, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2003 | 290 | |
| 2 | 1995 | 184 | |
| 3 | 1990 | 150 | |
| 4 | 2000 | 144 | |
| 5 | 1991 | 108 | |
| 6 | 1999 | 106 | |
| 7 | 1990 | 93 | |
| 8 | 2001 | 91 | |
| 9 | 1996 | 88 | |
| 10 | 1996 | 74 | |
| 11 | 1993 | 65 | |
| 12 | 1999 | 47 | |
| 13 | 2004 | 29 | |
| 14 | 1989 | 28 | |
| 15 | Docetaxel combined with vinorelbine: phase I results and new study designs. | 1997 | 23 |
| 16 | 1997 | 21 | |
| 17 | 2001 | 20 | |
| 18 | Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type. | 2006 | 19 |
| 19 | 2003 | 18 | |
| 20 | 1990 | 18 |
About N. Azli
N. Azli is a scholar working on Oncology, Otorhinolaryngology, Dermatology, Surgery and Pulmonary and Respiratory Medicine, having authored 35 papers that have together received 1.7k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (18 papers), Head and Neck Cancer Studies (11 papers), Chemotherapy-related skin toxicity (10 papers), Viral-associated cancers and disorders (6 papers), Neutropenia and Cancer Infections (6 papers), Breast Cancer Treatment Studies (5 papers), HER2/EGFR in Cancer Research (5 papers) and Lung Cancer Treatments and Mutations (5 papers). The work is most often cited by research in Otorhinolaryngology (465 citations), Oncology (1.4k citations), Dermatology (323 citations), Cancer Research (494 citations) and Pulmonary and Respiratory Medicine (275 citations). N. Azli has collaborated with scholars based in France, Belgium and Spain. Frequent co-authors include Esteban Cvitkovic, A. Riva, Véronique Dièras, M. Bachouchi, P. Fumoleau, P. Wibault, Jean‐Pierre Armand, P Pouillart, Pierre Kerbrat and B Chevallier. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Annals of Oncology, Cancer and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.